Clinical Trial

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection
Trial Details
NCT Number NCT07146217
Lead Sponsor Saptalis Pharmaceuticals LLC
Collaborators: CBCC Global Research
Conditions Bacterial Infections
Enrollment 30 participants
Start Date 2025-08
Primary Completion 2026-07 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-08-28